PT 1-2

Drug Profile

PT 1-2

Alternative Names: PT 1.2; PTS1.2/A; SASPject PT1.2; SASPject PTSA1.2/A

Latest Information Update: 13 Apr 2016

Price : $50

At a glance

  • Originator Phico Therapeutics
  • Class Antibacterials; DNA-binding proteins
  • Mechanism of Action Bacterial DNA inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Staphylococcal infections

Most Recent Events

  • 13 Apr 2016 Phase I development is ongoing in United Kingdom
  • 23 Jul 2013 Phase-I development is ongoing in United Kingdom
  • 29 Jan 2009 Phico Therapeutics receives grant from Wellcome Trust for PT 1-2 development in Staphylococcal infections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top